SOAK: Policy Directions Unpredictable, Self-Developed E-liquids to Launch in March 2024

2Firsts EventsBusiness by 2FIRSTS
Dec.17.2023
SOAK: Policy Directions Unpredictable, Self-Developed E-liquids to Launch in March 2024
At the VAPE CLUB SHOW 2023 in Russia, Dmitry, representative of e-cigarette brand SOAK, discussed the future prospects of the Russian market.

On December 16th, Dmitry, representative of e-cigarette brand SOAK, engaged in a conversation with 2FIRSTS at the VAPE CLUB SHOW 2023 in Russia. During the discussion, Dmitry provided an in-depth analysis of the development prospects of the Russian market and the brand's future new plans.

SOAK: Policy Directions Unpredictable, Self-Developed E-liquids to Launch in March 2024
Product: Saok Image source: 2FIRSTS

 

The recently released e-cigarette regulatory policy by the Russian government has attracted widespread attention from the industry. Dmitry admitted that predicting the direction of the policy is exceptionally challenging.

 

He expressed that starting from March next year, Russia's ban on e-cigarette additives will be implemented, and the pace of strengthened regulation is astonishing. Unlike other countries, Russia has not reduced taxes but instead increased them by tenfold, posing significant challenges to the industry. However, he mentioned the example of Turkey where the sale of e-cigarettes is prohibited, yet e-cigarette stores are thriving, indicating that even under regulatory pressure, there is still enormous market potential for e-cigarettes.

 

Despite facing regulatory uncertainties, Dmitry remains optimistic about the prospects of the Russian market. He believes that the e-cigarette market in Russia is still expanding, with new products constantly emerging, indicating that the entire industry is still in its growth and upward phase.

 

Dmitry revealed that SOAK brand is considering launching a new product line in 2024 or 2025, which may include screen design. He emphasized that the brand remains committed to standing out from the crowd, focusing on unique design and independent research and development.

 

Dmitry mentioned that SOAK is set to launch a new product line in March next year, featuring their own in-house developed e-liquid blended with various natural flavors, promising a unique vaping experience.

 

In this innovative process, the support of a Chinese team has been obtained. SOAK will customize unique flavors based on the needs of users in the Russian region in order to meet the variations in consumer tastes in different areas.

 

Dmitry gives high praise to Chinese e-cigarette brands, stating that 99% of e-cigarettes are manufactured in Shenzhen, China. He believes that Chinese brands hold significant competitiveness in the market. He acknowledges customers' right to choose brands and expresses an open attitude towards Chinese brands as long as they do not affect SOAK's customers.

 

Dmitry shared the brand's marketing strategy, which involves developing through agency channels in Europe, the United States, and the Middle East. Additionally, increased investment will be allocated based on the performance in different regional markets. Logistics plays a crucial role in the expansion of the market, and SOAK plans to allocate substantial funds towards equipment and logistics to ensure the rapid and smooth delivery of products to the target markets.

 

We will allocate one million dollars for equipment and one and a half million dollars for logistics. This can still guarantee profitability. In Turkey, the cost of equipment logistics amounts to 23 dollars," Dmitry said.

 

In conclusion, Dmitry points out that an increasing number of people are recognizing the assistance e-cigarettes provide in quitting smoking. His personal experience also confirms this, as he quit smoking after 20 years and turned to using e-cigarettes. This further underscores the potential value of e-cigarettes in aiding smoking cessation.

 

At this exhibition, SOAK is looking forward to achieving even greater success in future market competition.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13